EUVIMEDEUVIMED entdecken
Crossref

Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy

Teppei Hagino iD, Akihiko Uchiyama iD, Keiji Kosaka, Takeshi Araki, Hidehisa Saeki iD, Eita Fujimoto, Sei-Ichiro Motegi iD, Naoko Kanda

Dermatitis® · 01.11.2026 · 37 (6) · 969-974

DOI: 10.1177/17103568251361929 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatitis®, online erschienen am 23.07.2025. Verfasst von Teppei Hagino und 7 weiteren Autor:innen. Beteiligte Einrichtung: From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The transition of blood biomarkers has not been precisely examined in real-world treatments with anti-interleukin (IL)-13 antibodies for atopic dermatitis (AD).

Objective

To evaluate the transition of blood biomarkers during 24-week treatment with lebrikizumab or tralokinumab for patients with AD in real-world settings, stratified by the presence or absence of prior systemic therapy.

Methods

We conducted a retrospective study of Japanese patients with AD who received lebrikizumab ( n = 148) or tralokinumab ( n = 173). We measured serum immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) at weeks 0, 4, 12, and 24 in systemic therapy-naïve or -experienced patients.

Results

IgE, TARC, and LDH decreased throughout the 24-week treatment with lebrikizumab or tralokinumab, while TEC transiently increased at week 4 or 12 in both systemic therapy-naïve and -experienced patients, and the magnitudes of decreasing IgE and TARC or increasing TEC were higher in the latter.

Conclusion

IgE, TARC, and LDH decreased during 24-week treatment with lebrikizumab or tralokinumab, while TEC transiently increased at week 4 or 12 in both systemic therapy- naïve and -experienced patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, MonoclonalHumansImmunoglobulin EBiomarkersChemokine CCL17Retrospective StudiesFemaleMaleL-Lactate DehydrogenaseAdultLeukocyte CountEosinophilsMiddle AgedYoung AdultAntibodies, Monoclonal, Humanized

Substanzen

Immunoglobulin EBiomarkersChemokine CCL17Antibodies, MonoclonalL-Lactate DehydrogenaselebrikizumabCCL17 protein, humantralokinumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Department of Dermatology, Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Sei-Ichiro Motegi

Zitieren

APA

Hagino, T., Uchiyama, A., Kosaka, K., Araki, T., Saeki, H., Fujimoto, E., Motegi, S. I., & Kanda, N. (2026). Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy. Dermatitis®, 37(6), 969-974. https://doi.org/10.1177/17103568251361929

Vancouver

Hagino T, Uchiyama A, Kosaka K, Araki T, Saeki H, Fujimoto E, et al. Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy. Dermatitis®. 2026;37(6):969-974. doi:10.1177/17103568251361929

BibTeX
@article{Hagino2026,
  author = {Hagino, Teppei and Uchiyama, Akihiko and Kosaka, Keiji and Araki, Takeshi and Saeki, Hidehisa and Fujimoto, Eita and Motegi, Sei-Ichiro and Kanda, Naoko},
  title = {Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy},
  journal = {Dermatitis®},
  year = {2026},
  volume = {37},
  number = {6},
  pages = {969--974},
  doi = {10.1177/17103568251361929}
}
Kostenlos starten →